Introduction {#s1}
============

Prostate cancer is the fifth leading cause of cancer-related deaths worldwide, and it is also one of the most common malignant tumors among men in developed countries ([@B1]). Prostate cancer accounted for nearly one-fifth of all newly diagnosed cancers in the United States in 2018 ([@B2]). The main treatments for localized prostate cancer include radical prostatectomy (RP), external beam radiation therapy (EBRT) and brachytherapy (BT) of the prostate ([@B3], [@B4]). Patients with localized prostate cancer can choose from a variety of treatment options. A systematic review showed that EBRT, BT and RP were effective monotherapies for localized prostate cancer and that BT had a similar biochemical progression-free survival (bPFS) rate as RP in patients with a low to moderate risk of prostate cancer ([@B5]). The results of randomized clinical trials have shown that EBRT combined with BT, compared to EBRT monotherapy, improves the bPFS rates of patients with intermediate- and high-risk prostate cancer ([@B6], [@B7]).

However, a retrospective trial found that BT reduced biochemical failure in patients with predominantly intermediate- and high-risk disease compared with EBRT alone ([@B8]). Prostate BT not only has a better therapeutic effect but also obvious dosimetric advantages and lower costs compared with EBRT ([@B9], [@B10]). Hormone therapy (HT) has been shown to improve the prognoses of patients with locally advanced prostate cancer receiving EBRT ([@B11]). BT has become an increasingly popular treatment option for localized prostate cancer. Lee et al. believe that BT combined with HT can improve the bPFS rates of patients compared with BT monotherapy ([@B12]), whereas others argue that BT combined with HT does not improve the bPFS rates of patients compared with BT monotherapy ([@B13], [@B14]). However, there is a lack of systematic reviews on the application of BT combined with HT in patients with prostate cancer.

In this meta-analysis, we aimed to determine whether BT combined with HT could increase the bPFS and overall survival (OS) rates of patients with localized prostate cancer.

Materials and Methods {#s2}
=====================

The study protocol is registered through PROSPERO, and the registration number is CRD42019126003, which can be found online at <https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=126003>.

Search Strategy
---------------

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria ([@B15]). A comprehensive search was conducted using the Medline ([www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed)), Web of Science (<http://apps.webofknowledge.com>), Cochrane Library ([www.cochranelibrary.com](http://www.cochranelibrary.com)) and Embase ([www.embase.com](http://www.embase.com)) databases for English language studies published between the databases\' dates of inception and February 2019. The searches involved a combination of medical-subject heading searches and text words. We searched these databases using the following terms: "prostate cancer," "prostate carcinoma," "prostatic neoplasms," "brachytherapy," "hormone," and "androgen." The detailed search strategy is shown in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}.

Inclusion and Exclusion Criteria
--------------------------------

The following inclusion criteria were developed to guide the selection of studies: (1) a clinical trial or a prospective or retrospective study; (2) a study design with an observation group that received a combination of BT combined with HT and a control group that received BT monotherapy; (3) original full-text articles designed to evaluate the association between a therapy and the bPFS or OS of patients with prostate cancer; and (4) studies utilizing appropriate statistical methods for analyses and having sufficient data.

The following studies were excluded from the meta-analysis: (1) reviews, letters, case reports, conference papers, and studies based on animal models or cell models; (2) duplicated studies; and (3) studies lacking sufficient data for extraction.

Study Selection and Data Extraction
-----------------------------------

Two reviewers independently screened titles and abstracts based on the above criteria and evaluated the eligibility of each study by reading the full text. Two researchers independently extracted data from the articles. Disagreements were resolved by consensus following a literature reanalysis. We extracted the following information from each included article: (1) general study information, including the first author, date of publication, country, and study design; (2) patient characteristics, including the number of participants, age and risk group; (3) treatment outcomes, including 5-year OS, 5-year bPFS, and 10-year bPFS; and (4) the methodological quality assessment index.

Quality Assessment
------------------

The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the included publications, as all of them were retrospective cohort studies ([@B16]). The assessment of quality using the NOS is based on three parameters: selection, comparability and outcomes. Studies can receive a maximum possible score of nine stars. NOS scores of 7--9 indicate high-quality reports, and scores of 4--6 represent medium-quality reports.

Statistical Analyses
--------------------

The clinical outcomes of interest included 5-year OS and 5-year and 10-year bPFS. All statistical analyses were performed using STATA 14.0 (College Station, Texas 77845, USA, Serial number: 401406267051). Relative risk (RR), as the effect size for OS or bPFS, was expressed along with the 95% confidence interval (CI). RRs \>1 and 95% CIs that did not overlap with 1 were indicators that BT combined with HT increased the length of OS or bPFS of patients with prostate cancer, whereas RRs \<1 were indicators that BT combined with HT did not increase the length of OS or bPFS of patients with prostate cancer. The heterogeneity was evaluated using the Higgins *I*^2^ test and Cochran\'s Q test, with a significance level of *I*^2^ \> 50% or *p* \> 0.1. Fixed-effect models were used for the initial analyses after random-effect models were performed for validation analyses if significant heterogeneity was present. Publication bias was assessed through Begg\'s funnel plot ([@B17]) and Egger\'s linear regression ([@B18]). If the two-tailed *P*-value yielded by Egger\'s test was \<0.1, Duval and Tweedie\'s trim and fill method for bias correction was used ([@B19]).

Results {#s3}
=======

Study Selection and Characteristics
-----------------------------------

We initially identified 558 potentially eligible studies using search terms. In the first screening, duplicate studies, reviews, letters, case reports, conference papers and studies based on animal models or cell models were excluded. The titles and abstracts of the remaining 139 studies were carefully reviewed, and 110 studies with irrelevant subjects were excluded. Two studies were excluded because they were published by the same institution. A full-text review of the remaining 27 studies was conducted to exclude studies that did not have survival data or did not fully meet the inclusion criteria. Finally, 16 studies with 9,359 patients ([@B12]--[@B14], [@B20]--[@B32]) were ultimately included in this study. A detailed outline of the process of study selection is presented in [Figure 1](#F1){ref-type="fig"}.

![Flow diagram of the process by which the studies included in the analysis were selected.](fonc-10-00169-g0001){#F1}

All 16 studies were retrospective in nature; five were published in Europe (Germany, the UK and Italy), and 11 were published in North America (Canada and the USA). A total of 16 studies with 9,359 patients were analyzed, including 4,175 who were treated with BT combined with HT and 5,184 treated with HT monotherapy. Of all the studies, three reported 5-year OS rates of patients with prostate cancer, 12 reported 5-year bPFS rates, and four reported 10-year bPFS rates. The characteristics and clinical results of the included studies are summarized in [Table 1](#T1){ref-type="table"}. According to the NOS, the quality of the 16 studies was high, and the individual ratings for each study are presented in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics of the studies included in the meta-analysis.

  **Study (year)**             **Study design**   **Country**   **Median age (year)**   **Treatment method**   **Number of patients (*****n*****)**   **Risk group (*****n*****)**   **5-year OS rate**   **5-year bPFS rate**   **10-year bPFS rate**                                                 
  ---------------------------- ------------------ ------------- ----------------------- ---------------------- -------------------------------------- ------------------------------ -------------------- ---------------------- ----------------------- ----- ------- ------- ------- ------- ------- -------
  Zimmermann et al. ([@B20])   RCS                Germany       NA                      BT + HT                BT                                     205                            705                  316                    572                     22    NA      NA      94.6%   94.6%   NA      NA
  Pickles et al. ([@B13])      RCS                Canada        69                      BT + HT                BT                                     121                            139                  NA                     NA                      NA    NA      NA      86%     85%     NA      NA
  Boehm et al. ([@B21])        RCS                Europe        69                      BT + HT                BT                                     213                            206                  67                     276                     76    93%     92%     86%     74%     NA      NA
  Strom et al. ([@B22])        RCS                America       65                      BT + HT                BT                                     55                             65                   0                      92                      28    100%    98%     94.5%   93.8%   NA      NA
  Dickinson et al. ([@B23])    RCS                UK            62                      BT + HT                BT                                     231                            807                  1038                   0                       0     NA      NA      96.8%   93.4%   NA      NA
  Guarneri et al. ([@B24])     RCS                Italy         68.3                    BT + HT                BT                                     52                             115                  103                    53                      NA    NA      NA      79.1%   89%     NA      NA
  Yamoah et al. ([@B25])       RCS                America       NA                      BT + HT                BT                                     525                            863                  963                    369                     56    NA      NA      NA      NA      89.3%   83.4%
  Kubicek et al. ([@B26])      RCS                America       70                      BT + HT                BT                                     588                            236                  329                    300                     195   NA      NA      81.6%   80.1%   45.4%   35.9%
  Peters et al. ([@B27])       RCS                America       67                      BT + HT                BT                                     975                            762                  761                    400                     576   NA      NA      95.6%   88.8%   NA      NA
  D\'Amico et al. ([@B28])     RCS                America       72.7                    BT + HT                BT                                     254                            221                  0                      0                       475   96.9%   93.2%   NA      NA      NA      NA
  Merrick et al. ([@B29])      RCS                America       68                      BT + HT                BT                                     119                            85                   0                      0                       204   NA      NA      NA      NA      91.6%   79.7%
  Stone et al. ([@B30])        RCS                America       67                      BT + HT                BT                                     64                             215                  146                    0                       133   NA      NA      NA      NA      94%     75%
  Ash et al. ([@B31])          RCS                UK            63                      BT + HT                BT                                     346                            321                  NA                     NA                      NA    NA      NA      76.1%   72.6%   NA      NA
  Lee et al. ([@B12])          RCS                America       68                      BT + HT                BT                                     133                            68                   0                      66                      135   NA      NA      79%     54%     NA      NA
  Merrick et al. ([@B32])      RCS                America       68                      BT + HT                BT                                     162                            245                  157                    162                     88    NA      NA      99.4%   92.2%   NA      NA
  Potters et al. ([@B33])      RCS                America       NA                      BT + HT                BT                                     132                            131                  NA                     NA                      NA    NA      NA      87.1%   86.9%   NA      NA

*RCS, Retrospective Cohort Study; EG, Experimental Group; CG, Control Group; BT, brachytherapy; HT, hormone therapy; OS, Overall survival; Bpfs, Biochemical progression-free survival; NA, Not Available*.

###### 

The Newcastle-Ottawa Scale (NOS) for assessing the quality of the cohort studies.

  **Studies**                  **Selection**   **Comparability**   **Assessment of outcome**   **Total score**                            
  ---------------------------- --------------- ------------------- --------------------------- ----------------- ---- ---- ---- ---- ---- ---
  Zimmermann et al. ([@B20])   \*              \*                                              \*                \*        \*   \*   \*   7
  Pickles et al. ([@B13])      \*              \*                                              \*                \*        \*   \*   \*   7
  Boehm et al. ([@B21])        \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Strom et al. ([@B22])        \*              \*                                              \*                \*        \*   \*   \*   7
  Dickinson et al. ([@B23])    \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Guarneri et al. ([@B24])     \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Yamoah et al. ([@B25])       \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Kubicek et al. ([@B26])      \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Peters et al. ([@B27])       \*              \*                  \*                          \*                \*        \*   \*   \*   8
  D\'Amico et al. ([@B28])     \*              \*                  \*                          \*                \*   \*   \*   \*   \*   9
  Merrick et al. ([@B29])      \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Stone et al. ([@B30])        \*              \*                                              \*                \*        \*   \*   \*   7
  Ash et al. ([@B31])          \*              \*                                              \*                \*        \*   \*   \*   7
  Lee et al. ([@B12])          \*              \*                  \*                          \*                \*   \*   \*   \*   \*   9
  Merrick et al. ([@B32])      \*              \*                  \*                          \*                \*        \*   \*   \*   8
  Potters et al. ([@B33])      \*              \*                  \*                          \*                \*        \*   \*   \*   8

Biochemical Progression-Free Survival
-------------------------------------

Twelve studies provided the number of patients in the experimental and control groups and their 5-year bPFS rates. A forest plot of the association between BH combined with HT and the 5-year bPFS rates of patients with prostate cancer is shown in [Figure 2](#F2){ref-type="fig"}. However, our analysis uncovered evidence of the presence of heterogeneity among the studies (Q = 31.4, *I*^2^ = 65.0%, *P* = 0.001, Tau^2^ = 0.0014). The results of the heterogeneity test are shown in Additional file: [Supplementary Table S2](#SM2){ref-type="supplementary-material"}. Therefore, we used a random-effects model to analyze the relationship between BT combined with HT and the 5-year bPFS rates of patients with prostate cancer. The summary RR for the relationship was 1.04 (95% CI: 1.01--1.08). This result indicated that BT combined with HT increased the 5-year bPFS rates of patients with prostate cancer compared with BT monotherapy. In order to find the source of the heterogeneity, we conducted a subgroup analysis in which the studies were organized into subgroups by geographic region (where they were conducted) or age of the patients. We found that BT combined with HT did not increase the 5-year bPFS rates of patients with prostate cancer in studies from Europe (RR = 1.04, 95% CI: 0.97--1.13, *P* = 0.201) and that the heterogeneity among these studies was high (Q = 13.13, *I*^2^ = 69.5%; *P* = 0.011, Tau^2^ = 0.0019). However, BT combined with HT increased the 5-year bPFS rates of patients with prostate cancer in studies from North America (RR = 1.05, 95% CI: 1.01--1.09, *P* = 0.007), but the heterogeneity among these studies was also high (Q = 13.02, *I*^2^ = 53.9%; *P* = 0.043, Tau^2^ = 0.0011) ([Figure 3A](#F3){ref-type="fig"}). In the other subgroup analysis ([Figure 3B](#F3){ref-type="fig"}), the heterogeneity among the indicated studies was low (Q = 0.49, *I*^2^ = 0.00%; *P* = 0.783, Tau^2^ = 0.0000) in the studies with a median age ≤65 years, but the heterogeneity among the indicated studies was high (Q = 17.94, *I*^2^ = 66.5%; *P* = 0.006, Tau^2^ = 0.0021) in the studies with a median age of 65--75 years. We conducted an interactive analysis and found that there were no significant differences between subgroups in different regions (*Z* = −0.78, *P* = 0.436) or in the different median age subgroups (*Z* = −01.32, *P* = 0.186). At the same time, we performed sensitivity analyses to verify the effect of each study on the overall estimate by omitting a study each time and determining the overall estimates for the remaining studies. The results of the sensitivity analysis showed good consistency and indicated that ignoring any one of the studies did not significantly affect the combined estimate; the range of the results was quite narrow. The results of the sensitivity analyses are shown in [Figure 5](#F5){ref-type="fig"}. Our results indicated that the pooled estimate of our analysis was statistically robust.

![Forest plots of the association between BT combined with HT and the 5-year bPFS rates in patients with prostate cancer. RR, Relative Risk; CI, Confidence Interval.](fonc-10-00169-g0002){#F2}

![**(A)** Subgroup analyses by region. **(B)** Subgroup analyses by median age. RR, Relative Risk; CI, Confidence Interval.](fonc-10-00169-g0003){#F3}

Four studies provided the number of patients in the experimental and control groups and their 10-year bPFS rates. A forest plot of the association between BH combined with HT and the 10-year bPFS rates of patients with prostate cancer is shown in [Figure 4A](#F4){ref-type="fig"}. Our analysis revealed that these studies had high heterogeneity (Q = 28.26, *I*^2^ = 89.4%, *P* = 0.001, Tau^2^ = 0.0063), so we used a random-effects model. The summary RR for the relationship was 1.12 (95% CI: 1.02--1.23), indicating that BT combined with HT also increased the 10-year bPFS rates of patients with prostate cancer compared with BT monotherapy.

![**(A)** Forest plots of the association between BT combined with HT and the 10-year bPFS rates of patients with prostate cancer. **(B)** Forest plots of the association between BT combined with HT and the 5-year OS rates of patients with prostate cancer. RR, Relative Risk; CI, Confidence Interval.](fonc-10-00169-g0004){#F4}

![Sensitivity analysis of the 5-year bPFS rates of patients with prostate cancer.](fonc-10-00169-g0005){#F5}

Overall Survival
----------------

Three studies provided the number of patients in the experimental and control groups and their 5-year OS rates. A forest plot of the association between BH combined with HT and the 5-year OS rates of patients with prostate cancer is shown in [Figure 4B](#F4){ref-type="fig"}. Our analysis revealed that this study had little heterogeneity (Q = 0.97, *I*^2^ = 0.0%, *P* = 0.616, Tau^2^ = 0.0000), so we used a fixed-effects model. However, the summary RR for the relationship was 1.02 (95% CI: 0.99--1.10). This result indicated that BT combined with HT, compared with BT monotherapy, was positively associated with the 5-year OS rates of patients with prostate cancer, although the association was not significant.

Publication Bias
----------------

Publication bias was assessed using Begg\'s funnel plots and Egger\'s test ([Figure 6](#F6){ref-type="fig"}). The results indicated that there was no publication bias for the analysis of the 5-year bPFS rates (Begg\'s test, *P* = 1.00; Egger\'s test, *P* = 0.963). As the number of studies included in the analyses of the 10-year bPFS rates and 5-year OS rates was small (\<10), we did not construct a funnel plot. Because the test efficiency is low when the studies are too few, it is not enough to test if the funnel diagram is asymmetric ([@B34]).

![Publication bias test for evaluating the 5-year bPFS rates of patients with prostate cancer. **(A)** Begg\'s funnel plot with pseudo 95% confidence limits and **(B)** Egger\'s publication bias plot.](fonc-10-00169-g0006){#F6}

Discussion {#s4}
==========

Through a systematic review of the literature, 16 studies on BT combined with HT in the treatment of localized prostate cancer from North America and Europe were analyzed in a meta-analysis, which is the most comprehensive review of this topic at present.

BT includes short-term implant therapy and permanent-particle implant therapy, of which 125I or 103Pd implants are currently the most popular forms of implant therapy ([@B33]). After accurate positioning by the three-dimensional system, the radioactive source is sealed and placed directly into the prostate for implantation treatment. Prostate cancer brachytherapy was first performed by Barringer in 1915 ([@B35], [@B36]) and was adopted for the first time in the 1970s, when the retro-pubic method was widely used ([@B37]). Ultrasound-guided permanent prostatic implantation appeared in the early 1980s and has been used worldwide. Holm and his colleagues first described the ultrasound-guided transperineal technique in 1983 ([@B38]). Sylvester et al. reported the treatment of 215 cases of localized prostate cancer with 125I seed implantation alone. The follow-up period was 15 years, and the disease-free survival rate was 80.4% ([@B39]). Similarly, in a study with 5- and 10-year follow-ups, Martinez et al. reported OS rates of 94% and 84%, respectively, among 700 patients treated with 125I seed implantation ([@B40]). The report further confirmed the satisfactory long-term efficacy of BT for the treatment of prostate cancer. BT has also been used to treat breast cancer ([@B41], [@B42]), skin cancer ([@B43]), lung cancer ([@B44], [@B45]), head and neck tumors ([@B46]), esophageal cancer ([@B47], [@B48]), bile duct cancer ([@B49]), soft tissue sarcomas ([@B50]), and gynecological tumors ([@B51]). Furthermore, BT has been found to be a highly effective and safe treatment, providing a good alternative to surgical removal of the prostate, breast and cervix while reducing the risks of some long-term side effects ([@B52]).

HT is one of the main treatments for advanced or metastatic prostate cancer, and the role of HT in localized prostate cancer has received increasing attention in the research literature ([@B53]). Multiple prospective trials of men with localized prostate cancer have shown that RT combined with HT improves overall survival compared with RT alone ([@B54]--[@B56]). The rationale supporting the combination of HT and RT is based on an inference about patients with prostate cancer from a large number of randomized RT trials. EBRT combined with HT has been shown to improve survival through increased local control ([@B57]). This therapy is suitable for patients with intermediate-risk and high-risk prostate cancer ([@B58]). As stated in the Introduction, Lee et al. reported improved bPFS rates of patients with prostate cancer who received BT combined with HT ([@B12]). However, the findings of some studies are inconsistent with the above results. To address this controversy, we conducted a meta-analysis to clarify the efficacy of BT combined with HT, and our data showed that BT combined with HT increased the 5-year (RR = 1.04, 95% CI: 1.01--1.08) and 10-year (RR = 1.12, 95% CI: 1.02--1.23) bPFS rates of patients with prostate cancer compared with BT monotherapy. However, BT combined with HT, compared with BT monotherapy, did not increase the 5-year OS rates of patients with prostate cancer.

Although HT is well-tolerated by most patients, it is associated with some adverse medical sequelae. For example, HT has been reported to increase the risk of fractures ([@B59]), obesity, hyperlipidemia, diabetes and metabolic syndrome ([@B60]). However, in our meta-analysis, these events were not reported in the 16 articles we included, so we were unable to conduct a comparative analysis. Whether BT combined with HT has the potential to increase the incidence of these complications requires a large number of randomized controlled trials to confirm.

This meta-analysis has the following advantages. First, it seems to be the first meta-analysis to evaluate whether BT combined with HT can increase 5-year or 10-year bPFS rates and 5-year OS rates of patients with prostate cancer. The results showed that BT combined with HT increased the 5-year and 10-year bPFS rates but not the 5-year OS rates. Second, a sensitivity analysis showed that the results did not change significantly after removing any one of the studies from the meta-analysis, indicating that the results are very robust. Finally, the 16 studies included in the meta-analysis were from different countries (giving it good representativeness), with high NOS scores and strict adherence to our inclusion and exclusion criteria, indicating that the quality of the studies was high and the results were applicable to the general population. Therefore, the results of the meta-analysis are stable and reliable.

However, this study has several limitations. First, the number of included studies that provided 5-year OS rates or 10-year bPFS rates in the analysis was small (\<10); therefore, we did not generate a funnel plot and were unable to detect publication bias. Second, we were unable to account for the influence of some important confounding factors that might have affected the results of our comprehensive analysis. Finally, the original studies did not provide data on treatment-related side effects, so comprehensive subgroup analyses were not performed. Although randomized trials provide the strongest evidence, there is not always reliable evidence in the field of oncology. Clinical practice is often based on observational studies, multiple small trials and even clinical experience alone ([@B61]). Therefore, a meta-analysis might be one of only a few available research methods for assessing the effectiveness and efficacy of clinical treatments.

In summary, BT combined with HT increased the bPFS rates of patients with localized prostate cancer, but the combination did not improve their OS rates. The results of this study provide new ideas for the treatment of localized prostate cancer in the future. As this study was a meta-analysis of retrospective cohort studies, further prospective randomized controlled studies are needed to reach reliable conclusions.

Author Contributions {#s5}
====================

XZ, DJ, MD, and XH designed and conceived the research. ZL, YL, and XZ searched the database. XZ and JC analyzed the data. DJ, BH, JL, and XH wrote the draft. All authors reviewed the manuscript and approved the final manuscript.

Conflict of Interest
--------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We would like to thank the Chinese Evidence Based Medicine Center at West China Hospital of Sichuan University for providing the Stata 14.0 statistical software.

Supplementary Material {#s6}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2020.00169/full#supplementary-material>

###### 

Click here for additional data file.

###### 

Click here for additional data file.

[^1]: Edited by: Ronald M. Bukowski, Cleveland Clinic, United States

[^2]: Reviewed by: Xin Xu, College of Medicine, Zhejiang University, China; Michael A. Feuerstein, Lenox Hill Hospital, United States

[^3]: This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology

[^4]: †These authors have contributed equally to this work
